426 related articles for article (PubMed ID: 38002034)
1. GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy.
Złotek M; Kurowska A; Herbet M; Piątkowska-Chmiel I
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002034
[TBL] [Abstract][Full Text] [Related]
2. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
Ferrari F; Moretti A; Villa RF
Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
[TBL] [Abstract][Full Text] [Related]
4. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
[TBL] [Abstract][Full Text] [Related]
6. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors.
Singh AK; Singh R
World J Diabetes; 2022 Jun; 13(6):466-470. PubMed ID: 35800411
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
Fei Y; Tsoi MF; Cheung BMY
Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224
[TBL] [Abstract][Full Text] [Related]
8. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Chewcharat A; Takkavatakarn K; Isaranuwatchai S; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Int Urol Nephrol; 2020 Sep; 52(9):1733-1745. PubMed ID: 32524495
[TBL] [Abstract][Full Text] [Related]
10. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
11. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Lamos EM; Hedrington M; Davis SN
Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
[TBL] [Abstract][Full Text] [Related]
12. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
14. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.
Tian S; Jiang J; Wang J; Zhang Z; Miao Y; Ji X; Bi Y
Diabetes Metab Res Rev; 2023 Oct; 39(7):e3673. PubMed ID: 37302139
[TBL] [Abstract][Full Text] [Related]
15. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
16. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.
Brønden A; Christensen MB; Glintborg D; Snorgaard O; Kofoed-Enevoldsen A; Madsen GK; Toft K; Kristensen JK; Højlund K; Hansen TK; Søndergaard E; Hansen KB
Diabet Med; 2023 Aug; 40(8):e15157. PubMed ID: 37249579
[TBL] [Abstract][Full Text] [Related]
17. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review.
Koshatwar M; Acharya S; Prasad R; Lohakare T; Wanjari M; Taksande AB
Cureus; 2023 Sep; 15(9):e44763. PubMed ID: 37809189
[TBL] [Abstract][Full Text] [Related]
19. Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.
Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
Curr Med Chem; 2020; 27(39):6658-6681. PubMed ID: 31604406
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
